

Open trials at INT

Trial	Sponsor	Type	Agent	Histology	Line	
STRADA	<i>Italian Sarcoma Group</i> INT: 67/17 PI: S. Stacchiotti	<u>Ph 2</u> No Profit Randomized Open-label	Trabectidin VS Doxorubicin + DTIC	SFT	Any	
TRABEPIO	<i>Mario Negri</i> INT: 37/21 PI: R. Sanfilippo	<u>Ph 2</u> No profit	Trabectedin + pioglitazone	Myxoid Liposarcoma	2+	
ERASING	<i>Italian Sarcoma Group</i> INT: 47/19 PI: S. Stacchiotti	<u>Ph 2</u> No profit	Eribulin	SFT	2+	
MCS-ISG	<i>Italian Sarcoma Group</i> INT: 39/21 PI: S. Stacchiotti	<u>Ph 2</u> No profit	Trabectedin	Mesenchymal chondrosarcoma	2+	

Open trials at INT

Trial	Sponsor	Type	Agent	Histology	Line	
TRASTS	<i>GEIS</i> INT: 64/15 PI: A. Gronchi	<u>Ph 1-2</u> No profit	Trabectedin + RT	STS	naïve	
TRAVELL	<i>ISG – Mario Negri</i> INT: 122/13 PI: R. Sanfilippo	<u>Ph 2</u> No profit	Trabectedina	Retroperitoneal LMS and LPS		
STRASS-2	<i>EORTC</i> INT: 187/20 PI: A. Gronchi	<u>Ph 3</u> No profit	Surgery +/- DOX/DTIC (LMS) or DOX/IFX (LPS)	Retroperitoneal HG- LMS and HG-DDLPS	naïve	
ISG-ACCeSS	<i>Italian Sarcoma Group</i> INT: 111/20 PI: S. Stacchiotti	<u>Ph 2</u> No profit	TSR-042	Clear Cell Sarcoma	0, 1, 2	

Open trials at INT

Trial	Sponsor	Type	Agent	Histology	Line	
GEIS-52 (ImmunoSARC 2)	<i>GEIS</i> INT:210/17 PI: S. Stacchiotti	<u>Ph 2</u> No profit	Sunitinib + Nivolumab	In Italy: - Cohort 1: only dedifferentiated chondrosarcoma subcohort - Cohort 2 EMC - Cohort 3 VS: closed due to interim analysis. - Cohort 5 ASPS (only 1 spot left) - Cohort 6 CCS (1 spot left which is reserved for a patient that is already on screening)	2+	
DCC-3014-03-001 (MOTION)	Deciphera Pharmaceuticals, LLC. INT: 228/21 PI: Stacchiotti	<u>Ph3 Randomized vs placebo</u> profit	Vimseltinib	TGCT	Any, but previously treated with anti-CSF1	
DCC-3014-01-001	<i>Deciphera Pharmaceuticals, LLC.</i> INT: 18/20 PI: S. Stacchiotti	<u>Ph 2</u> Profit	DCC-3014	TGCT	Arm B: 2+ (but previously treated with imatinib and/or nilotinib)	

Open trials at INT

Trial	Sponsor	Type	Agent	Histology	Line	
Ph2 INBRX-109 SA CS	Inhibrx INT: 08/22 PI: Stacchiotti	<u>Ph2</u> <u>Profit</u>	INBRX-109	Advanced conventional chondrosarcoma (not DD)	Any	